Artal Group S.A. Nanobiotix S.A. Transaction History
Artal Group S.A.
- $214 Million
- Q3 2024
Shares
1 transactions
Others Institutions Holding NBTX
# of Institutions
11Shares Held
6.43MCall Options Held
0Put Options Held
0-
Johnson & Johnson New Brunswick, NJ5.62MShares$16.8 Million10.31% of portfolio
-
Perceptive Advisors LLC New York, NY555KShares$1.66 Million0.08% of portfolio
-
Black Rock Inc. New York, NY239KShares$714,6330.0% of portfolio
-
Citigroup Inc3.42KShares$10,2340.0% of portfolio
-
Ubs Group Ag3.1KShares$9,2690.0% of portfolio
About Nanobiotix S.A.
- Ticker NBTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,875,900
- Market Cap $104M
- Description
- Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cance...